Articles tagged with Antivirals
Patients who undergo liver transplantation for hepatitis B-related liver damage are at risk of disease recurrence if antiviral treatment is withdrawn, according to a new study. Researchers found that these patients lack cellular immunity against the disease, making lifelong antiviral therapy necessary.
Researchers document increasing resistance to adamantane-based antiviral drugs in over 30% of H5N1 samples. The study provides a framework for monitoring global evolution of drug resistance using molecular evolution tests and geographic visualization techniques.
Researchers analyzed 700 genome sequences of avian influenza strains to document resistance to adamantane antivirals. The study suggests that widespread antiviral drug use can accelerate the evolution of drug-resistant viruses, which can spread rapidly.
Researchers identified a small molecule called sfRNA that controls host response to viral infection. Targeting this molecule could lead to effective antiviral therapy for flavivirus diseases.
UT Southwestern researchers have developed a new strategy for broad-spectrum anti-viral drugs that targets a lipid molecule on infected cells, triggering the immune system to attack and destroy infected cells. The treatment, bavituximab, shows promise in treating viral diseases, including Lassa fever and cytomegalovirus.
Scientists discovered a key step in HIV's attack on brain cells and were able to reverse its effects by blocking the receptor. The discovery opens up a new avenue for researchers to explore in preventing or treating HIV's neurological effects, which have no currently approved treatment.
The NIAID has awarded a contract to the University of Washington to analyze and model virus-host interactions for SARS and bird flu. The research program will use systems biology approaches to generate predictive models that can be experimentally validated, providing valuable resources for the scientific community.
Researchers have developed a novel method to rapidly select anti-HBV agents for chronic hepatitis B patients with drug resistance. The approach involves replicating clinical HBV isolates in an in vitro model system, allowing for the identification of antiviral agents such as adefovir that can inhibit HBV replication.
Researchers have shown that early treatment for Hepatitis C virus (HCV) within the first months following an infection develops a rapid poly-functional immune response against HCV. This finding suggests that early treatment can restore immune response and help eliminate the virus rapidly, contributing to the development of new treatments.
A study of 883 treatment-naïve HIV patients found that atazanavir/ritonavir once daily was as effective as lopinavir/ritonavir twice daily in reducing viral load and increasing CD4 cells. The once-daily regimen had less gastrointestinal toxicity but a higher rate of hyperbilirubinemia, supporting its use as a first-line treatment option.
Researchers discovered that imiquimod, an immune response modifier, relies on the Opioid Growth Factor (OGF)-OGF receptor axis for its action. This finding provides new insights into the mechanism of imiquimod's antiviral and antitumor activity.
Researchers modelled pandemic flu to guide national planning, finding that prompt implementation of social-distancing measures combined with antiviral treatment and prophylaxis can reduce influenza cases by 83-94%.
A study of patients with chronic hepatitis C found that silymarin, a popular herbal supplement, had no effect on HCV virus activity or liver inflammation. However, users reported fewer symptoms and improved quality of life compared to non-users.
New research reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity. Additionally, studies on cardiac development and wound healing have identified novel genes and mechanisms, offering potential therapeutic targets for chronic viral infections and cutaneous wounds.
New study reveals that timing of IL-7 treatment is crucial for enhancing antiviral immunity in mice. Administering IL-7 during the immune response contraction phase improves viral control and boosts vaccine-induced CD8+ T cell memory.
A Phase 2 study found eltrombopag increased platelet counts in 74% of patients with low platelet counts and cirrhosis due to hepatitis C. The drug also allowed more patients to complete antiviral therapy, with 36-65% completing treatment at the lowest and highest doses.
The Crimean Congo hemorrhagic fever virus uses protein 'knives' to cut bonds between cellular proteins, evading the immune system's defense. This allows the virus to replicate and spread, leading to high mortality rates. The discovery provides insight into why the virus is so virulent.
Researchers found that eltrombopag boosted platelet counts in a majority of patients with low platelet counts and cirrhosis due to HCV infection, allowing most to continue or start conventional antiviral treatment. The study's results are an important development for people infected with the hepatitis C virus worldwide.
A study found that antiviral medications significantly reduced the risk of death from flu in hospitalized adults, even when given up to four days after symptom onset. The research supports the use of antivirals for treating hospitalized patients with influenza.
The report warns that inadequate pandemic planning, including poor on-the-ground administration and delivery of antivirals and vaccines, could threaten EU security. The survey found that few countries have defined plans for distribution of antivirals or specific guidance on vaccine storage and administration.
A study found that Tamiflu is not removed or degraded during normal sewage treatment, leading to high levels of the drug in surrounding waters. This increases the risk of influenza viruses developing resistance to the medication, posing a threat to public health.
Research finds patients with lower levels of HCV antibody titer tend to have a brighter clinical outcome. Co-infection by hepatitis B and A viruses is associated with a higher possibility of self recovery, possibly due to interference with virus replication.
General Practitioners (GPs) are still over-prescribing antibiotics for common infections like sore throats and sinusitis, hindering efforts to combat antibiotic resistance. The analysis of the world's largest primary care database found that prescriptions for these conditions rose to 80% despite guidance warnings.
A new survey reveals that chronic hepatitis B patients often misunderstand the nature of their disease and its treatment. Despite being aware of the long-term consequences of the virus, many patients do not comply with their medication regimens, highlighting the need for improved patient education. The study suggests that enhanced pati...
Researchers will continue to study the antiviral, anti-inflammatory and immune-boosting mechanisms of Echinacea and Hypericum. The center aims to improve understanding of the characteristics of extracts that contribute to human health benefits.
Researchers at St. Jude Children's Research Hospital found that intramuscular injections of peramivir for 8 days protected mice from lethal H5N1 influenza virus infection and inhibited virus replication. This study supports the use of peramivir to control influenza during a pandemic.
A recent study in Japan found partial resistance to neuraminidase inhibitors among influenza B viruses, which may have implications for treatment and prevention strategies. The emergence of these resistant variants poses a significant concern, as they can cause infections with no difference in duration or clinical outcome.
The UGA-Emory collaboration will study influenza virus adaptation, transmission, and human immune responses. Researchers will also explore the genetic factors of flu spread and develop new antivirals.
A mathematical model suggests that widespread use of antiviral drugs like oseltamivir can quickly spread resistant viruses, even if they emerge rarely. Prophylaxis and treatment with oseltamivir would still delay the onset of the pandemic and reduce its total size.
A mathematical model predicts that international cooperation on sharing antiviral drugs is key to slowing down the spread of a bird flu pandemic. The 'reproductive number' of the virus plays a critical role in determining its potential for global spread.
Researchers found antiviral drugs highly effective in preventing seasonal flu illness, with oseltamivir at 81% efficacy. Treatment also reduced infectiousness, particularly with oseltamivir, but further studies are needed to confirm results.
Chronic kidney disease affects a significant portion of the UK population, particularly elderly individuals taking multiple medications. Healthcare professionals require specific guidance on using drugs that can cause or be altered by kidney disease, as 'use with caution' advice is often insufficient.
A new drug, eltrombopag, stimulates blood platelet production, enabling patients with low platelets to take standard antiviral medications. The trial found that 95% of patients responded with increased platelets and were able to start therapy.
A study reviewing 45 national pandemic influenza plans found that countries have not consistently prioritized who should receive vaccines, antivirals, ventilators, face masks, and other critical resources. Healthcare workers are often prioritized, but with varying criteria among countries.
A new study found that 30% of nations have not prioritized either vaccine nor drugs, while 49% prioritize antiviral drugs and 62% prioritize flu vaccines. The allocation decisions vary across countries, with healthcare workers consistently ranked top, but a wide variation in choosing next in line.
Researchers at the University of Wisconsin-Madison have discovered a novel peptide that effectively blocks influenza viruses, including deadly avian influenza, from entering host cells. The new finding offers a potential tool for preventing and treating influenza, which is losing its potency due to evolution.
Experimental drugs show promise against neuroAIDS, a growing concern despite best antivirals. New grant aims to protect brain from HIV-related nerve damage using compounds that counter toxins and reduce inflammation.
A comprehensive review of SARS treatment efficacy has found no evidence that any treatments were effective in treating the virus. The review examined 54 SARS treatment studies and 15 in-vitro studies but concluded that none of the treatments were successful.
Researchers at UT Southwestern Medical Center found that giving pregnant women with a history of genital herpes an anti-viral drug significantly lowers the rate of C-sections needed to protect infants from becoming infected. The study, involving 338 women, showed a 69% reduction in clinical herpes simplex virus at delivery.
Researchers have developed a new approach to target different diseases using short interfering RNA (siRNA) with tailored cellular properties. Human trials for siRNA-based anti-cancer and anti-viral treatments are currently underway in the USA and Europe, offering promising results.
The hepatitis C virus uses its protease activity to destroy a key antiviral signaling protein called MAVS, preventing infected cells from producing type 1 interferon. This allows the virus to evade the immune system and persist indefinitely, highlighting potential new treatment strategies.
A small study found that antiviral therapy with acyclovir and valacyclovir can significantly reduce postherpetic neuralgia symptoms in patients with moderate to severe nerve pain following shingles. Eight out of 15 participants reported a significant reduction in pain after one month of treatment.
Researchers have discovered that the sweetgum tree contains significant amounts of shikimic acid, a key ingredient in the production of Tamiflu, a treatment for bird flu. This finding could help alleviate the global shortage of the drug, which has sparked concerns over a potential pandemic.
A new study calls for equal access to Hepatitis C treatment for young injection drug users, citing low reinfection and completion rates among this group. The research suggests that denying treatment due to substance use can be counterproductive, as it often fails to address underlying health issues.
A CDC study found alarmingly high adamantane resistance rates of 92% among influenza A viruses isolated from patients in the US. Rapid surveillance is critical to prevent resistant viruses from spreading, especially in vulnerable populations like nursing homes.
A new web model of influenza-host lifecycles will help scientists understand how the virus interacts with its host, enabling the design of more effective anti-viral drugs. The Reactome database outlines a typical virus life cycle and will be updated as research becomes available.
Researchers found that two classes of antivirals prevented flu symptoms but not infection, and did not stop virus shedding. Dr. Tom Jefferson advises against using these drugs for seasonal influenza control, citing low effectiveness and potential adverse effects.
The threat of an avian influenza pandemic is growing, but health professionals can take measures to contain outbreaks and prepare for potential human-to-human transmission. Quarantining methods, antiviral medications, and international cooperation are key strategies that can help prevent or mitigate a pandemic.
The Geneva summit aims to address critical issues in preventing the spread of H5N1 influenza, including early detection of new clusters, effective surveillance systems, and strategies to avoid resistance to antivirals. The event seeks to promote global cooperation and coordination in addressing this pandemic threat.
Researchers found HIV-infected patients with effective antiviral therapy continually replenish their viral reservoir. Latently infected CD4+ T cells may become reactivated, spreading virions to nearby cells. A new strategy involves co-administering a reagent to dampen cellular activation.
Researchers urge Australia to issue compulsory licences, enabling local generic manufacturers to produce antiviral therapies at lower costs. This move would enhance the country's preparedness for pandemics, particularly in high-risk regions like Indonesia.
A team of researchers has developed an antiviral inhibitor that is active against several coronaviruses, including those causing the common cold and SARS. The compound targets the main protease enzyme, which is crucial for viral replication, and shows promise as a potential treatment for coronavirus-related diseases.
Researchers found that early intervention could slow the pandemic by reducing morbidity until a well-matched vaccine is produced. A combination of targeted antiviral drugs, quarantine, and prevaccination was effective in containing outbreaks with relatively moderate viral reproductive numbers.
A new computer model developed by Howard Hughes Medical Institute researchers can predict the spread of a potential influenza pandemic and identify effective containment strategies. The model uses demographic information and data on past influenza pandemics to simulate the virus's transmission and track its spread.
UCSB has been awarded two NIH Program of Excellence (PEN) grants in nanotechnology, totaling $25.5 million, to develop nanoscale agents for diagnosing and treating pulmonary artery disease and detecting vulnerable plaque. The projects aim to create targeted nanoparticles that can deliver diagnostic systems and therapeutic agents direct...
Researchers at Purdue University found that the flexible structure of WIN compounds allows them to shimmy into the proteins forming the virus' outer shell and alter them. This could potentially stop the infection process. The team believes WIN compounds may be effective in stabilizing proteins, preventing the viral trap door from opening.
Scientists found that a small form of APOBEC3G repels HIV, while a large form is ineffective; blocking the small form makes resting cells susceptible to infection. The discovery shifts the paradigm on how HIV infects T cells.
Researchers discovered a new way to stop smallpox by inhibiting host cell signaling pathways. Inhibitors already used in human cancer therapy may have widespread applications in treating viral infections and protecting against smallpox.
Researchers developed a novel antiviral treatment using RNA interference to inhibit respiratory syncytial virus (RSV) infection in mice. The treatment, administered as a nasal drop or spray, successfully suppressed the virus's NS1 protein, preserving the host's natural antiviral defense.
The report recommends the development of antiviral drugs against smallpox due to its high lethality and ease of transmission. Research on poxvirus mechanisms and animal models is crucial to understand how the virus kills and develop effective treatments without using antiviral drugs.